These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37841433)

  • 1. Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial.
    Asensi-Cantó A; Rodríguez-Braun E; Beltrán-Videla A; Hurtado AM; Conesa-Zamora P
    Front Oncol; 2023; 13():1238464. PubMed ID: 37841433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New role of the antidepressant imipramine as a Fascin1 inhibitor in colorectal cancer cells.
    Alburquerque-González B; Bernabé-García M; Montoro-García S; Bernabé-García Á; Rodrigues PC; Ruiz Sanz J; López-Calderón FF; Luque I; Nicolas FJ; Cayuela ML; Salo T; Pérez-Sánchez H; Conesa-Zamora P
    Exp Mol Med; 2020 Feb; 52(2):281-292. PubMed ID: 32080340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erratum: Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial.
    Frontiers Production Office
    Front Oncol; 2024; 14():1405306. PubMed ID: 38690162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells.
    Montoro-García S; Alburquerque-González B; Bernabé-García Á; Bernabé-García M; Rodrigues PC; den-Haan H; Luque I; Nicolás FJ; Pérez-Sánchez H; Cayuela ML; Salo T; Conesa-Zamora P
    J Mol Med (Berl); 2020 Mar; 98(3):383-394. PubMed ID: 31996952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo.
    Alburquerque-González B; Bernabé-García Á; Bernabé-García M; Ruiz-Sanz J; López-Calderón FF; Gonnelli L; Banci L; Peña-García J; Luque I; Nicolás FJ; Cayuela-Fuentes ML; Luchinat E; Pérez-Sánchez H; Montoro-García S; Conesa-Zamora P
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer.
    Vignjevic D; Schoumacher M; Gavert N; Janssen KP; Jih G; Laé M; Louvard D; Ben-Ze'ev A; Robine S
    Cancer Res; 2007 Jul; 67(14):6844-53. PubMed ID: 17638895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells.
    Park SH; Song JY; Kim YK; Heo JH; Kang H; Kim G; An HJ; Kim TH
    Int J Oncol; 2014 Mar; 44(3):637-46. PubMed ID: 24378809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
    Bardia A; Pusztai L; Albain K; Ciruelos EM; Im SA; Hershman D; Kalinsky K; Isaacs C; Loirat D; Testa L; Tokunaga E; Wu J; Dry H; Barlow W; Kozarski R; Maxwell M; Harbeck N; Sharma P
    Ther Adv Med Oncol; 2024; 16():17588359241248336. PubMed ID: 38686016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial.
    Rodríguez-Rubio M; Figueira JC; Acuña-Castroviejo D; Borobia AM; Escames G; de la Oliva P
    Trials; 2020 Aug; 21(1):699. PubMed ID: 32758298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of fascin-1 is involved in HIF-1α-dependent invasion and migration of hypopharyngeal squamous cell carcinoma.
    Bu M; Liu X; Liu X; Xu W
    Int J Oncol; 2019 Aug; 55(2):488-498. PubMed ID: 31268159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fascin1 in carcinomas: Its regulation and prognostic value.
    Ma Y; Machesky LM
    Int J Cancer; 2015 Dec; 137(11):2534-44. PubMed ID: 25302416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
    Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
    Trials; 2015 Dec; 16():575. PubMed ID: 26673577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.